Editas grabs orphan drug status for sickle cell disease CRISPR therapy
The CRISPR-based gene therapy received the designation from the US FDA for the second time, having previously secured the label in beta-thalassemia.
The CRISPR-based gene therapy received the designation from the US FDA for the second time, having previously secured the label in beta-thalassemia.
